These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27993684)

  • 1. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
    Biswas N
    Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths.
    Zhang Y; Che E; Zhang M; Sun B; Gao J; Han J; Song Y
    Int J Pharm; 2014 Oct; 473(1-2):375-83. PubMed ID: 25051114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multilayer encapsulated mesoporous silica nanospheres as an oral sustained drug delivery system for the poorly water-soluble drug felodipine.
    Hu L; Sun H; Zhao Q; Han N; Bai L; Wang Y; Jiang T; Wang S
    Mater Sci Eng C Mater Biol Appl; 2015 Feb; 47():313-24. PubMed ID: 25492202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan.
    Zhang Y; Zhi Z; Jiang T; Zhang J; Wang Z; Wang S
    J Control Release; 2010 Aug; 145(3):257-63. PubMed ID: 20450945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
    Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
    Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac.
    Kumar D; Sailaja Chirravuri SV; Shastri NR
    Int J Pharm; 2014 Jan; 461(1-2):459-68. PubMed ID: 24368106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
    Chella N; Daravath B; Kumar D; Tadikonda RR
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs.
    Zhang Y; Wang J; Bai X; Jiang T; Zhang Q; Wang S
    Mol Pharm; 2012 Mar; 9(3):505-13. PubMed ID: 22217205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.
    Chella N; Tadikonda R
    Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesoporous silica as topical nanocarriers for quercetin: characterization and in vitro studies.
    Sapino S; Ugazio E; Gastaldi L; Miletto I; Berlier G; Zonari D; Oliaro-Bosso S
    Eur J Pharm Biopharm; 2015 Jan; 89():116-25. PubMed ID: 25478737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mesoporous silica nanoparticle with charge-convertible pore walls for efficient intracellular protein delivery.
    Park HS; Kim CW; Lee HJ; Choi JH; Lee SG; Yun YP; Kwon IC; Lee SJ; Jeong SY; Lee SC
    Nanotechnology; 2010 Jun; 21(22):225101. PubMed ID: 20453291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel chitosan-functionalized spherical nanosilica matrix as an oral sustained drug delivery system for poorly water-soluble drug carvedilol.
    Sun L; Wang Y; Jiang T; Zheng X; Zhang J; Sun J; Sun C; Wang S
    ACS Appl Mater Interfaces; 2013 Jan; 5(1):103-13. PubMed ID: 23237208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
    Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
    Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-Functionalized Mesoporous Silica Nanoparticles for Celecoxib Delivery: Amine Grafting and Imidazolyl PEI Gatekeepers for Enhanced Loading and Controlled Release with Reduced Toxicity.
    Mudhakir D; Sadaqa E; Permana Z; Mumtazah JE; Zefrina NF; Xeliem JN; Hanum LF; Kurniati NF
    Molecules; 2024 Jul; 29(15):. PubMed ID: 39124951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboxylated mesoporous carbon microparticles as new approach to improve the oral bioavailability of poorly water-soluble carvedilol.
    Zhang Y; Zhi Z; Li X; Gao J; Song Y
    Int J Pharm; 2013 Sep; 454(1):403-11. PubMed ID: 23850816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
    Cao QR; Liu Y; Xu WJ; Lee BJ; Yang M; Cui JH
    Int J Pharm; 2012 Sep; 434(1-2):325-33. PubMed ID: 22688251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets.
    Zhao Z; Gao Y; Wu C; Hao Y; Zhao Y; Xu J
    Drug Dev Ind Pharm; 2016; 42(2):199-208. PubMed ID: 26114553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
    Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
    Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
    Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
    Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
    Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.